These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27716991)

  • 1. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
    Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW
    Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
    Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
    Santos C; Morgan BW; Geller RJ
    Am J Emerg Med; 2017 May; 35(5):802.e7-802.e8. PubMed ID: 27884585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
    Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
    Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
    Zurayk M; Keung YK; Yu D; Hu EH
    J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report of capecitabine toxicity and use of uridine triacetate.
    Oliver WD; Duffy AP; Hausner PF
    J Oncol Pharm Pract; 2019 Mar; 25(2):470-473. PubMed ID: 28942723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
    Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
    J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of uridine triacetate for the management of fluorouracil overdose.
    McEvilly M; Popelas C; Tremmel B
    Am J Health Syst Pharm; 2011 Oct; 68(19):1806-9. PubMed ID: 21930638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
    Ison G; Beaver JA; McGuinn WD; Palmby TR; Dinin J; Charlab R; Marathe A; Jin R; Liu Q; Chen XH; Ysern X; Stephens O; Bai G; Wang Y; Dorff SE; Cheng J; Tang S; Sridhara R; Pierce W; McKee AE; Ibrahim A; Kim G; Pazdur R
    Clin Cancer Res; 2016 Sep; 22(18):4545-9. PubMed ID: 27401247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A; Ezzeldin H; Fourie J; Diasio R
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [5-FU: At last!].
    Robert J
    Bull Cancer; 2019 Mar; 106(3):173-174. PubMed ID: 30837157
    [No Abstract]   [Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
    Brutcher E; Christensen D; Hennessey Smith M; Koutlas JB; Sellers JB; Timmons T; Thompson J
    Clin J Oncol Nurs; 2018 Dec; 22(6):627-634. PubMed ID: 30451997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
    Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
    Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.